We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




First-of-its-Kind Blood Test Detects Trauma-Related Diseases

By LabMedica International staff writers
Posted on 24 Apr 2025

In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. More...

Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret these stress signals as threats, similar to an infection. This misinterpretation triggers an autoimmune response, where the immune system mistakenly attacks the body, resulting in a cycle of inflammation. The longer this cycle persists, the greater the damage to both mental and physical health. Studies have shown that chronic inflammation leads to oxidative stress in the brain, a condition that contributes to mental health challenges such as anxiety, depression, and other disorders. This inflammation doesn’t just affect mental health; it also leads to a range of physical conditions, including autoimmune disorders, cardiovascular diseases, and chronic pain. Essentially, unresolved trauma and prolonged stress disrupt the body’s response systems, ultimately affecting behavior, personality, and overall well-being. Now, a simple blood test can identify biological markers of trauma-induced conditions before the onset of disease.

iXpressGenes (Huntsville, AL, USA) has discovered that prolonged stress and trauma can lead to differentiated inflammation and autoimmune responses in the body. These immune responses can result in serious trauma-induced diseases, including post-traumatic stress disorder (PTSD), autoimmune conditions, chronic pain syndromes, cardiovascular diseases, and more. These conditions can be detected through specific RNA biomarkers. iXpressGenes has developed a diagnostic aid using a biomarker technology that revolutionizes early detection and prevention of PTSD, anxiety, and depression, thereby modernizing mental health care. Identifying these biomarkers may aid in preventing and treating trauma-induced diseases, such as PTSD, autoimmune disorders, and chronic pain syndromes. The company’s Trauma Autoimmune Indicator (TAI) test is a proprietary, blood-based RNA biomarker technology that helps healthcare professionals detect biological changes caused by trauma, enabling proactive prevention of trauma-related diseases.

TAI screening represents a breakthrough in trauma care by detecting trauma-induced inflammation at the cellular level before symptoms appear. By analyzing RNA and identifying specific protein dysregulations associated with immune response, TAI screening reveals the hidden changes trauma causes in the body. This early detection not only helps identify the impact of trauma but also provides valuable insights for timely intervention, reducing the risk of long-term health complications. Just like how a cholesterol test aids in preventing heart attacks and other cardiovascular conditions through early intervention, early detection of trauma-related biomarkers can help providers shift from reactive treatment to proactive prevention of trauma-induced diseases.

Related Links:
iXpressGenes


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.